AbstractHIVViral Hepatitis and Liver DiseaseAPACC 2020Association of body mass index with immune recovery, virologic failure and cardiovascular disease risks among people living with HIVView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseAPACC 2020Factors associated with high alanine aminotransferase (ALT) and cirrhosis in people living with HIV on combination antiretroviral treatment (cART) in the Asia-PacificView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseAPACC 2020The Changes of Health-Related Quality-of-Life and Sleep Quality Following the Switch of Anti- Retroviral Treatment in Patients with Well-Controlled HIV Infection.View Abstract
AbstractHIVViral Hepatitis and Liver DiseaseAPACC 2020Switch-rate and switch-pattern of patients on 2-drug antiretroviral treatment – comparison to 3-drug regimen in a Japanese hospital claim databaseView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseAPACC 2020Analysis of total HIV-1DNA in peripheral blood after HAART in HIV-1/ HCV co-infected patientsView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseAPACC 2020Anti-Müllerian hormone levels and related factors of 715 HIV-infected women in childbearing ageView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseAPACC 2020The impact of gender on the clinical course of HIV infection in Yangon, MyanmarView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseAPACC 2020Safety and Efficacy of Genvoya® (Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide, EVG/C/F/TAF) from the 3rd year Post Market Surveillance (PMS) Data in KoreaView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseAPACC 2020Treatment Persistence among HIV-1 Patients Initiating Antiretroviral Therapy in JapanView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseAPACC 2020Assessment of the safety of dolutegravir in HIV-infected patients from China: A real-world, open-label, multicenter, post-marketing surveillance studyView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseAPACC 2020Efficacy and Safety of Switching to B/F/TAF in Virologically Suppressed Asian Women living with HIVView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseAPACC 2020Pooled Analysis of the Efficacy, Safety, and Health Outcomes Following 48 Weeks of Long-acting Cabotegravir and Rilpivirine Maintenance Therapy for HIV-1 Infection in Phase 3 ATLAS and FLAIR Studies: Sub-Analysis in Asian PopulationsView Abstract
